It is well established in NSCLC, CRC and other solid tumors that responses to KRAS inhibitors are variable; combination strategies in development will depend on characterization of the diverse genomic landscape of KRAS mutant cancers both pre-treatment and upon acquired resistance to therapies29–31. The gene discussed is KRAS; the disease is colorectal carcinoma.